REGN Jun 2025 970.000 put
| Previous close | 43.80 |
| Open | 42.90 |
| Bid | 27.00 |
| Ask | 36.00 |
| Strike | 970.00 |
| Expiry date | 2025-06-20 |
| Day's range | 42.90 - 43.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
BloombergRegeneron Shares Head for Worst Month Since 2019 on Legal Ruling
(Bloomberg) -- Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.Most Read from BloombergVanderbilt Leases Struggling NYC Seminary for Campus ExpansionClimate Migrants Stand to Overwhelm World’s MegacitiesNJ Transit, Amtrak Trains Delayed After Derailment Near NYCWhere Cargo Bikes Are Freeing Cities From Polluting Van
Investor's Business DailyRegeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
GlobeNewswireDupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for al
